Parsippany, New Jersey. Edenbridge Pharmaceuticals, LLC is pleased to announce the launch of two new molecules into the U.S. market: Diclofenac Sodium Extended-Release Tablets, USP, a generic version of Voltaren®*-XR Tablets and Venlafaxine Extended-Release Tablets. Diclofenac Sodium Extended-Release Tablets, USP are indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. Venlafaxine Extended-Release Tablets are indicated for the treatment of major depressive disorder and social anxiety disorder. For more information, please contact the Company directly at info@dexcelpharmausa.com.
Diclofenac Sodium Extended-Release Tablets, USP and Venlafaxine Extended-Release Tablets, USP Launch
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.